Topics: Research
Brian Kalasek is both a father of a young son with PWS and VP of Special Risk for Mutual of Omaha insurance company. In this 76-minute presentation, he shares successful strategies for maximizing health insurance benefits and estate planning — inform...
In this 88‑minute video, Dr. Deepan Singh discusses what anxiety looks like in PWS, what leads to it, and how can it be treated. Learn from this PWS mental health presentation, which concludes with Dr. Singh answering questions from the audience at t...
Topics: Research
In the last 5 years, more than 15 human clinical trials have taken place evaluating possible treatments for PWS. FPWR has been closely involved in each and every one: contributing the patient perspective to aspects of study design, funding or helping...
Topics: Research
In 2020, more than 9,500 donors supported PWS research and our mission to eliminate the challenges of PWS. We would like to thank all of our supporters: everything we do is made possible by you! Here are just a few of our accomplishments from this pa...
Topics: Research
Two recently released studies represent good first steps to identifying possible uses of probiotic supplementation in PWS. The studies looked at effects of probiotic use on constipation, abdominal fat, fasting insulin and insulin resistance levels, w...
Topics: Research
2021 brings new opportunities to learn even more about PWS and improve the health of those living with PWS. De-identified data from the Global PWS Registry is actively being used to help PWS physicians understand medical problems in PWS, provide scie...
If you value PWS research and want to help find treatments for PWS, join us for a panel of parents and hear how they've taken action in their own unique ways. In this 50‑minute video, active PWS parents and fundraisers talk about how they've gotten c...
Topics: Research
Radius Health has announced its acquisition of RAD011, a synthetic cannabidiol oral solution, which may be a potential treatment for hyperphagia in people with Prader-Willi Syndrome. The Company plans to initiate a pivotal Phase 2/3 study for patient...